BWX Technologies, Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

BWX Technologies: Cheaper After the 43% Drawdown, Still Priced on Cash ...

Acquisition Dividend AI-generated analysis

πŸ“‰ BWXT shares fell 40% to $139, trading near a yearly low despite a record $8.4 billion Navy reactor backlog.

πŸ’° The company generated only $317 million in free cash flow last year, down 12%, even as revenue rose 23%.

🏭 BWXT is expanding its Cambridge, Ontario plant by roughly 40% to support heavy nuclear manufacturing growth.

πŸ“œ Management guides revenue to $3.8 billion for the current year, with nearly all growth driven by nuclear contracts.

πŸ’Έ The stock trades at approximately 40x trailing free cash flow and a yield of just 2.5%.

πŸ”„ BWXT sold its medical-isotopes business for up to $800 million to fund reinvestment in reactor expansion.

🎯 The company targets $550 million in annual free cash flow by 2030 with revenue near $6 billion.

βš“ BWXT is the sole U.S. manufacturer of reactors for Navy submarines and aircraft carriers.

πŸ“ˆ A recent $189 million contract award for naval nuclear fuel was announced days before the article's publication.

πŸ›οΈ The company holds a modest net debt of about $1.4 billion against a market cap of roughly $12.7 billion.

Bullish Signals
  • BWX Technologies is the sole U.S. manufacturer of nuclear reactors for Navy submarines and aircraft carriers, securing non-competitive, multi-year demand.
  • The company secured an additional $189 million contract to manufacture naval nuclear fuel, reinforcing its stable backlog position.
  • Revenue is expected to grow significantly as the company converts its record backlog into distributable cash flow by 2030.
  • Management plans to expand EBITDA margins from approximately 17.5% this year to around 20% by 2030.
Risk Factors
  • Free cash flow shrank by roughly 12% last year despite a 23% increase in revenue due to heavy capital spending.
  • The stock trades at approximately 40 times trailing free cash flow, implying the market is pricing in future growth rather than current earnings power.
  • Current dividend yields are less than one percent, offering no income anchor while the company reinvests heavily in expansion.
Full Analysis
BWX Technologies (BWXT) shares have declined approximately 40% from their yearly highs, trading near $139 despite possessing a robust backlog of roughly $8.4 billion for U.S. Navy nuclear reactors. The company is the sole domestic manufacturer of these critical defense systems, holding a unique non-competitive position that ensures stable and predictable demand. Recent activity includes an $189 million contract award for naval nuclear fuel, reinforcing the strength of its core industrial business. However, the stock's valuation remains elevated relative to current cash generation capabilities. While revenue has grown by 23% year-over-year, free cash flow contracted by roughly 12% to approximately $317 million. The market prices the equity at about 40 times trailing free cash flow, reflecting a bet on future expansion rather than immediate income. Capital expenditures are consuming significant liquidity as the company expands its manufacturing footprint in Ontario and converts its backlog into physical components. Management has outlined a strategic plan to reach $550 million in annual free cash flow by 2030, targeting revenue near $6 billion and expanding EBITDA margins from 17.5% to 20%. To fund this industrial scaling, BWXT agreed to sell its medical-isotopes unit for up to $800 million while retaining a minority stake. The investment thesis relies entirely on the successful conversion of backlog into distributable cash over the next four years, as current yields remain low at roughly 2.5%.